KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $251.3 million.

  • Recursion Pharmaceuticals' Cash from Financing Activities rose 142678.9% to $251.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400.2 million, marking a year-over-year increase of 695.6%. This contributed to the annual value of $304.1 million for FY2024, which is 11702.24% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Cash from Financing Activities stood at $251.3 million, which was up 142678.9% from $97.7 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Cash from Financing Activities peaked at $463.7 million during Q2 2021, and registered a low of -$11.1 million during Q3 2021.
  • Its 5-year average for Cash from Financing Activities is $76.1 million, with a median of $13.9 million in 2024.
  • Data for Recursion Pharmaceuticals' Cash from Financing Activities shows a peak YoY increase of 12128874.35% (in 2021) and a maximum YoY decrease of 10482.98% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Cash from Financing Activities stood at $3.8 million in 2021, then skyrocketed by 3779.24% to $147.3 million in 2022, then tumbled by 45.23% to $80.7 million in 2023, then crashed by 86.81% to $10.6 million in 2024, then soared by 2262.44% to $251.3 million in 2025.
  • Its Cash from Financing Activities was $251.3 million in Q3 2025, compared to $97.7 million in Q2 2025 and $40.5 million in Q1 2025.